<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00819390</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG A5258</org_study_id>
    <secondary_id>1U01AI068636</secondary_id>
    <nct_id>NCT00819390</nct_id>
  </id_info>
  <brief_title>Chloroquine for Reducing Immune Activation in HIV- Infected Individuals</brief_title>
  <official_title>A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Clinical Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV is characterized by frequent immune system activation. Early in the course of infection
      the body establishes an immune activation &quot;set point&quot; related to the amount of HIV in the
      blood stream. This set point affects the rate of CD4 cell loss. Without CD4 cells, or with
      very low levels of CD4 cells, the body cannot fight off illness. This is known as
      immunodeficiency. If left untreated HIV can lead to extreme immunodeficiency and AIDS.

      Evidence suggests that by decreasing the rate of immune system activation, immune deficiency
      progression could be prevented. The purpose of this study is to learn how well chloroquine
      can reduce the level of immune activation and to test the safety and tolerance of chloroquine
      in people infected with HIV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HIV is characterized by persistent immune system activation, and early in the course of
      infection the body establishes an immune activation &quot;set point&quot; related to the amount of HIV
      in the blood stream. This set point affects the rate of CD4 cell loss. Without CD4 cells, or
      with very low levels of CD4 cells, the body cannot fight off illness. This is known as
      immunodeficiency. If left untreated HIV can lead to extreme immunodeficiency and AIDS.

      Immune system activation includes activating the CD8 cells. These cells attack body cells
      infected with viruses. Because of this, CD4 cells infected with HIV are frequently destroyed
      by CD8 cells. The purpose of this study is to learn how well chloroquine reduces the level of
      activation of CD8 cells in people infected with HIV. Increased activation of CD8 cells is
      thought to lead to a more severe path of disease in HIV infection.

      The constant immune activation observed in HIV- infected patients has also been linked to
      higher levels of byproducts from certain naturally occurring bacteria found in the gut that
      are known to be immune stimulants. By decreasing the stimulation from these byproducts with
      chloroquine treatment, HIV disease may be slowed.

      The purpose of this study was to learn how well chloroquine reduces the level of activation
      of CD8 cells and lowers the levels of bacteria byproducts in people infected with HIV, either
      off antiretroviral therapy (ART) (protocol version 1.0 dated December 17, 2008) or on-ART
      (protocol version 2.0 dated October 1, 2010). The off-ART (Arms A and B) and on-ART (Arms C
      and D) participants were enrolled during different time periods, and the study was designed
      to analyze the two study populations separately. This study also looked at how well
      chloroquine was tolerated and its safety in HIV- infected participants.

      Off-ART participants in the study were randomized with equal probability to one of two
      treatment arms:

      Arm A: Participants received 12 weeks of chloroquine treatment followed by 12 weeks of
      placebo

      Arm B: Participants received 12 weeks of placebo followed by 12 weeks of chloroquine

      On-ART participants in the study were randomized with equal probability to one of two
      treatment arms:

      Arm C: Participants received 12 weeks of chloroquine treatment followed by 12 weeks of
      placebo

      Arm D: Participants received 12 weeks of placebo followed by 12 weeks of chloroquine

      Study treatment was given once a day for a full 24 weeks. There was an additional 4 weeks of
      follow-up for purposes of safety. After treatment has started, participants were asked to
      come to the clinic on Weeks 4, 10, 12, 16, 22, and 24. At each visit participants were given
      enough study treatment to last until the next visit. Each visit lasted between 30 and 60
      minutes. At most visits, participants had a physical exam, answered questions about any
      medications they were taking and how they are feeling, and had blood drawn for safety to
      assess CD4/CD8 cell counts and viral load. Some additional blood were also stored for
      immunology testing. At some visits, participants were asked questions about their medication
      and medical history, had pupils dilated, had a hearing test, and had an electrocardiogram
      (EKG). Some visits required participants to arrive fasting. Pregnancy tests were also
      conducted if the participant is able to become pregnant or if pregnancy was suspected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Percent CD8 HLA-DR+/CD38+ From Baseline to Week 12</measure>
    <time_frame>At pre-entry, entry, weeks 10 and 12</time_frame>
    <description>The baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Percent CD8 HLA-DR+/CD38+ From Start to End of the 12-week Chloroquine Treatment Period</measure>
    <time_frame>For Arms A and C: Pre-entry, entry, weeks 10 and 12. For Arms B and D: Weeks 10, 12, 22 and 24</time_frame>
    <description>For Arm A: Chloroquine then Placebo for off-ART participants and Arm C: Chloroquine then Placebo for on-ART participants, the baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+. For Arm B: Placebo then Chloroquine for off-ART participants and Arm D: Placebo then Chloroquine for on-ART participants, the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+ was subtracted from the mean of week 22 and week 24 percent CD8 HLA-DR+/CD38+.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percent CD8 HLA-DR+/CD38+ From Week 12 to Week 24</measure>
    <time_frame>At Weeks 10, 12, 22 and 24</time_frame>
    <description>The mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+ is subtracted from the mean of the week 22 and week 24 percent CD8 HLA-DR+/CD38+</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Percent CD8 HLA-DR+/CD38+ From Baseline to Week 24 in Arm A and Arm C</measure>
    <time_frame>At Pre-entry, entry, Weeks 22 and 24</time_frame>
    <description>The baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 22 and week 24 percent CD8 HLA-DR+/CD38+.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total CD4 T Cell Count From Baseline to Week 12</measure>
    <time_frame>At pre-entry, entry, weeks 10 and 12</time_frame>
    <description>Baseline CD4 count (mean of pre-entry and entry CD4 count) is subtracted from the mean of week 10 and week 12 CD4 count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Events Grade 3 or Higher</measure>
    <time_frame>From start of study treatment to study completion at week 28</time_frame>
    <description>Events included signs and symptoms, laboratory abnormalities and/or clinical events grade 3 or higher which were described by site clinician blinded to the treatment arm as definitely or possibly related to the study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-1 RNA Copies/mL at Study Entry for Off-ART Participants</measure>
    <time_frame>At Entry</time_frame>
    <description>Results reported are for HIV-1 RNA (copies/mL) at study entry for off-ART participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-1 RNA Copies/mL at Weeks 12 and 24 for Off-ART Participants</measure>
    <time_frame>At weeks 12 and 24</time_frame>
    <description>Results reported are for HIV-1 RNA (copies/mL) at week 12 and week 24 for off-ART participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-1 RNA Copies/mL at Study Entry for On-ART Participants</measure>
    <time_frame>At Entry</time_frame>
    <description>Results reported are for HIV-1 RNA at study entry for on-ART participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-1 RNA Copies/mL at Week 12 for On-ART Participants</measure>
    <time_frame>At week 12</time_frame>
    <description>Results reported are for HIV-1 RNA at week 12 for on-ART participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-1 RNA Copies/mL at Week 24 for On-ART Participants</measure>
    <time_frame>At week 24</time_frame>
    <description>Results reported are for HIV-1 RNA at week 24 for on-ART participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent CD8 CD38+ at Baseline</measure>
    <time_frame>At pre-entry and entry</time_frame>
    <description>Baseline CD8 CD38+ is computed as the mean of pre-entry and entry CD8 CD38+.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent CD8 CD38+ at Week 12</measure>
    <time_frame>At Week 12</time_frame>
    <description>Results reported are the week 12 percentage of CD8 expressing CD38+.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent CD8 CD38+ at Week 24</measure>
    <time_frame>At Week 24</time_frame>
    <description>Results reported are the week 24 percentage of CD8 expressing CD38+.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent CD4 HLA-DR+/CD38+ at Baseline</measure>
    <time_frame>At pre-entry and entry</time_frame>
    <description>Baseline CD4 HLA-DR+/CD38+ is computed as the mean of pre-entry and entry CD4 HLA-DR+/CD38+.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent CD4 HLA-DR+/CD38+ at Week 12</measure>
    <time_frame>At Week 12</time_frame>
    <description>Results reported are the week 12 percentage of CD4 expressing HLA-DR+/CD38+.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent CD4 HLA-DR+/CD38+ at Week 24</measure>
    <time_frame>At Week 24</time_frame>
    <description>Results reported are the week 24 percentage of CD4 expressing HLA-DR+/CD38+.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6, Soluble TNF-rI (sTNF-rI) and D-dimer at Baseline</measure>
    <time_frame>At pre-entry and entry</time_frame>
    <description>Baseline IL-6, sTNF-rI and D-dimer were computed as the mean of pre-entry and entry IL-6, sTNF-rI and D-dimer, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6, Soluble TNF-rI (sTNF-rI) and D-dimer at Week 12</measure>
    <time_frame>At week 12</time_frame>
    <description>Results reported are the week 12 IL-6, sTNF-rI and D-dimer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6, Soluble TNF-rI (sTNF-rI) and D-dimer at Week 24</measure>
    <time_frame>At week 24</time_frame>
    <description>Results reported are the week 24 IL-6, sTNF-rI and D-dimer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble CD14 (sCD14) at Baseline</measure>
    <time_frame>At pre-entry and entry</time_frame>
    <description>Baseline sCD14 was computed as the mean of pre-entry and entry sCD14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble CD14 (sCD14) at Week 12</measure>
    <time_frame>At week 12</time_frame>
    <description>Results reported are the week 12 sCD14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble CD14 (sCD14) at Week 24</measure>
    <time_frame>At week 24</time_frame>
    <description>Results reported are the week 24 sCD14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Lipopolysaccharides (LPS) at Entry</measure>
    <time_frame>At entry</time_frame>
    <description>Results reported are for entry fasting LPS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Lipopolysaccharides (LPS) at Week 12</measure>
    <time_frame>At week 12</time_frame>
    <description>Results reported are the week 12 fasting LPS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Lipopolysaccharides (LPS) at Week 24</measure>
    <time_frame>At week 24</time_frame>
    <description>Results reported are the week 24 fasting LPS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Activation Levels of Plasmacytoid Dendritic Cells (pDC) and Myeloid Dendritic Cells (mDC) at Baseline</measure>
    <time_frame>At pre-entry and entry</time_frame>
    <description>Baseline percent activation levels of pDC were computed as the mean of pre-entry and entry percent activation levels of pDC. Similarly, baseline percent activation levels of mDC were computed as the mean of pre-entry and entry percent activation levels of mDC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Activation Levels of Plasmacytoid Dendritic Cells (pDC) and Myeloid Dendritic Cells (mDC) at Week 12</measure>
    <time_frame>At week 12</time_frame>
    <description>Results reported are the week 12 percent activation levels of pDC and mDC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Activation Levels of Plasmacytoid Dendritic Cells (pDC) and Myeloid Dendritic Cells (mDC) at Week 24</measure>
    <time_frame>At week 24</time_frame>
    <description>Results reported are the week 24 percent activation levels of pDC and mDC.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>A: Chloroquine then Placebo for Off-ART Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Placebo then Chloroquine for Off-ART Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C: Chloroquine then Placebo for On-ART Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D: Placebo then Chloroquine for On-ART Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chloroquine</intervention_name>
    <description>Taken orally, once daily, at a dose of 250 mg for 12 weeks.</description>
    <arm_group_label>A: Chloroquine then Placebo for Off-ART Participants</arm_group_label>
    <arm_group_label>B: Placebo then Chloroquine for Off-ART Participants</arm_group_label>
    <arm_group_label>C: Chloroquine then Placebo for On-ART Participants</arm_group_label>
    <arm_group_label>D: Placebo then Chloroquine for On-ART Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Taken orally, once daily for 12 weeks.</description>
    <arm_group_label>A: Chloroquine then Placebo for Off-ART Participants</arm_group_label>
    <arm_group_label>B: Placebo then Chloroquine for Off-ART Participants</arm_group_label>
    <arm_group_label>C: Chloroquine then Placebo for On-ART Participants</arm_group_label>
    <arm_group_label>D: Placebo then Chloroquine for On-ART Participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infected

          -  Certain specified laboratory values obtained within 30 days prior to study entry. More
             information on this criterion can be found in the study protocol.

          -  Documentation that pre-entry specimen for the primary immune activation endpoint
             responses has been obtained

          -  Female participants of reproductive potential must have a negative pregnancy test
             performed within 24 hours prior to study entry

          -  If engaging in sexual activity, female participants must use adequate forms of
             contraception while receiving study treatment and for 4 weeks after stopping the
             treatment. More information on this criterion can be found in the study protocol.

          -  Ability and willingness to provide informed consent

        Additional Inclusion Criteria for Off-ART Participants:

          -  No antiretroviral therapy (ART) for at least 6 months prior to study entry and not
             likely to start within the 6 months after study entry

          -  CD4 cell count greater than or equal to 400 cells/mm3 at screening, obtained within 30
             days prior to study entry

          -  For participants with previous ART use, documentation or recall of nadir CD4 cell
             count greater than or equal to 200 cells/mm3

          -  HIV-1 RNA viral load greater than or equal to 1,000 copies/mL obtained within 30 days
             prior to study entry

          -  No history of CDC category C AIDS-related opportunistic infections

          -  Karnofsky performance score greater than or equal to 70 within 30 days prior to study
             entry

        Additional Inclusion Criteria for On-ART Participants:

          -  Receiving ART, defined as a regimen that includes three or more antiretroviral
             medications, for at least 24 months prior to study entry

          -  Required documentation that all HIV-1 viral loads (at least two) were below 400
             copies/mL. More information on this criterion can be found in the study protocol.

          -  Screening HIV-1 RNA &lt;200 copies/mL within 30 days prior to study entry. More
             information on this criterion can be found in the study protocol.

          -  CD4 cell count &lt;350 cells/mm3 at screening, obtained within 30 days prior to study
             entry

        Exclusion Criteria:

          -  Continuous use of certain specified medication for more than 3 days within 30 days
             prior to study entry. More information on this criterion can be found in the study
             protocol.

          -  Use of chloroquine or hydroxychloroquine within 3 months prior to study entry

          -  Known history of hypersensitivity to 4-aminoquinoline compounds (such as chloroquine
             or hydroxychloroquine)

          -  Active drug or alcohol use or dependence that, in the opinion of the investigator
             would interfere with adherence to study requirements

          -  Serious illness requiring systemic treatment and/or hospitalization within 30 days
             prior to study entry

          -  Renal insufficiency, defined as serum creatinine greater than 1.5 mg/dL, within 30
             days prior to study entry

          -  History of retinal disease (i.e. confirmed retinopathy by ophthalmologic examination)

          -  History of neoplasm, within 5 years prior to study entry, other than treated in situ
             carcinoma or basal-cell or localized squamous cell carcinoma of the skin

          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency at screening

          -  History of porphyria

          -  History of psoriasis

          -  History of cirrhosis

          -  History of seizure disorder

          -  History of tinnitus (ear and/or head noise lasting more than 5 minutes that occurs
             more often than once per week) or history of sudden hearing loss

          -  History of myopathy

          -  History of cardiac conduction abnormality or cardiomyopathy. More information on this
             criterion can be found in the study protocol.

        Additional Exclusion Criteria for On-ART Participants:

        - Plans to change ART regimen with the 6 months after study entry (change in ART regimen is
        only permitted if due to toxicity)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey M Jacobson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Drexel University College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Therapeutics CRS (5801)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ucsd, Avrc Crs (701)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital CRS (6101)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University CRS (GU CRS) (1008)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Adult AIDS CRS (201)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital ACTG CRS (101)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University CRS (2101)</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell CRS (7804)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unc Aids Crs (3201)</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Cincinnati CRS (2401)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case CRS (2501)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth CRS (2503)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. of the Univ. of Pennsylvania CRS (6201)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pittsburgh CRS (1001)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Therapeutics CRS (3652)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Neely M, Kalyesubula I, Bagenda D, Myers C, Olness K. Effect of chloroquine on human immunodeficiency virus (HIV) vertical transmission. Afr Health Sci. 2003 Aug;3(2):61-7.</citation>
    <PMID>12913796</PMID>
  </reference>
  <reference>
    <citation>Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis. 2003 Nov;3(11):722-7. Review.</citation>
    <PMID>14592603</PMID>
  </reference>
  <reference>
    <citation>Semrau K, Kuhn L, Kasonde P, Sinkala M, Kankasa C, Shutes E, Vwalika C, Ghosh M, Aldrovandi G, Thea DM. Impact of chloroquine on viral load in breast milk. Trop Med Int Health. 2006 Jun;11(6):800-3.</citation>
    <PMID>16772000</PMID>
  </reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2009</study_first_submitted>
  <study_first_submitted_qc>January 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2009</study_first_posted>
  <results_first_submitted>August 26, 2014</results_first_submitted>
  <results_first_submitted_qc>August 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 5, 2014</results_first_posted>
  <disposition_first_submitted>December 20, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>December 20, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 28, 2014</disposition_first_posted>
  <last_update_submitted>October 3, 2014</last_update_submitted>
  <last_update_submitted_qc>October 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chloroquine</mesh_term>
    <mesh_term>Chloroquine diphosphate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Version 1.0 of the study enrolled off antiretroviral therapy (ART) participants only. Off-ART participants were enrolled from March 2009 to July 2010.
On-ART participants were allowed to enroll in Version 2.0 of the study. On-ART participants were enrolled from December 2010 to November 2012.</recruitment_details>
      <pre_assignment_details>Analysis of data from off-ART and on-ART participants was done separately. The study analyses did not utilize the cross-over design, and the primary analysis consists of comparison between the chloroquine and placebo arms after the first 12 weeks on study in each off-ART and on-ART study populations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
          <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
          <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>C: Chloroquine Then Placebo for On-ART Participants</title>
          <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>D: Placebo Then Chloroquine for On-ART Participants</title>
          <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Results are for all participants, off-ART and on-ART, who enrolled in the study.</population>
      <group_list>
        <group group_id="B1">
          <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
          <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
          <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>C: Chloroquine Then Placebo for On-ART Participants</title>
          <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>D: Placebo Then Chloroquine for On-ART Participants</title>
          <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="18"/>
            <count group_id="B4" value="19"/>
            <count group_id="B5" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" lower_limit="29" upper_limit="43"/>
                    <measurement group_id="B2" value="39" lower_limit="35" upper_limit="44"/>
                    <measurement group_id="B3" value="50" lower_limit="48" upper_limit="55"/>
                    <measurement group_id="B4" value="49" lower_limit="41" upper_limit="56"/>
                    <measurement group_id="B5" value="46" lower_limit="36" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18-29 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30-39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-49 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-79 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Percent CD8 HLA-DR+/CD38+ From Baseline to Week 12</title>
        <description>The baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+.</description>
        <time_frame>At pre-entry, entry, weeks 10 and 12</time_frame>
        <population>Analysis used a modified as-treated approach, limited to participants with assay data at baseline and weeks 10 or 12, and with no break in study treatment for &gt;=14 days. Off-ART analysis excluded participants who started ART. On-ART analysis excluded participants who stopped ART or had virologic rebound (confirmed HIV-1 RNA&gt;1000 copies/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent CD8 HLA-DR+/CD38+ From Baseline to Week 12</title>
          <description>The baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+.</description>
          <population>Analysis used a modified as-treated approach, limited to participants with assay data at baseline and weeks 10 or 12, and with no break in study treatment for &gt;=14 days. Off-ART analysis excluded participants who started ART. On-ART analysis excluded participants who stopped ART or had virologic rebound (confirmed HIV-1 RNA&gt;1000 copies/mL).</population>
          <units>percent of CD8 expressing HLA-DR+/CD38+</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-10.0" upper_limit="9.0"/>
                    <measurement group_id="O2" value="-0.5" lower_limit="-2.3" upper_limit="2.8"/>
                    <measurement group_id="O3" value="-3.1" lower_limit="-4.3" upper_limit="0.4"/>
                    <measurement group_id="O4" value="-1.2" lower_limit="-3.3" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two arms/groups with respect to change in percent CD8 HLA-DR+/CD38+ from baseline to week 12.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.428</p_value>
            <p_value_desc>The p-value is not adjusted for multiple comparisons. The a priori threshold for statistical significance used for the two-sided test was 0.05.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>No other adjustments</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two arms/groups with respect to change in percent CD8 HLA-DR+/CD38+ from baseline to week 12.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.247</p_value>
            <p_value_desc>The p-value is not adjusted for multiple comparisons. The a priori threshold for statistical significance used for the two-sided test was 0.05.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>No other adjustments.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percent CD8 HLA-DR+/CD38+ From Start to End of the 12-week Chloroquine Treatment Period</title>
        <description>For Arm A: Chloroquine then Placebo for off-ART participants and Arm C: Chloroquine then Placebo for on-ART participants, the baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+. For Arm B: Placebo then Chloroquine for off-ART participants and Arm D: Placebo then Chloroquine for on-ART participants, the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+ was subtracted from the mean of week 22 and week 24 percent CD8 HLA-DR+/CD38+.</description>
        <time_frame>For Arms A and C: Pre-entry, entry, weeks 10 and 12. For Arms B and D: Weeks 10, 12, 22 and 24</time_frame>
        <population>Analysis used a modified as-treated approach, limited to participants with assay data at the required time points, and with no break in study treatment for &gt;=14 days. Off-ART analysis excluded participants who started ART. On-ART analysis excluded participants who stopped ART or had virologic rebound (confirmed HIV-1 RNA&gt;1000 copies/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent CD8 HLA-DR+/CD38+ From Start to End of the 12-week Chloroquine Treatment Period</title>
          <description>For Arm A: Chloroquine then Placebo for off-ART participants and Arm C: Chloroquine then Placebo for on-ART participants, the baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+. For Arm B: Placebo then Chloroquine for off-ART participants and Arm D: Placebo then Chloroquine for on-ART participants, the mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+ was subtracted from the mean of week 22 and week 24 percent CD8 HLA-DR+/CD38+.</description>
          <population>Analysis used a modified as-treated approach, limited to participants with assay data at the required time points, and with no break in study treatment for &gt;=14 days. Off-ART analysis excluded participants who started ART. On-ART analysis excluded participants who stopped ART or had virologic rebound (confirmed HIV-1 RNA&gt;1000 copies/mL).</population>
          <units>percent of CD8 expressing HLA-DR+/CD38+</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-10.0" upper_limit="9.0"/>
                    <measurement group_id="O2" value="1.5" lower_limit="-2.5" upper_limit="7.0"/>
                    <measurement group_id="O3" value="-3.1" lower_limit="-4.3" upper_limit="0.4"/>
                    <measurement group_id="O4" value="-2.9" lower_limit="-4.7" upper_limit="-0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percent CD8 HLA-DR+/CD38+ From Week 12 to Week 24</title>
        <description>The mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+ is subtracted from the mean of the week 22 and week 24 percent CD8 HLA-DR+/CD38+</description>
        <time_frame>At Weeks 10, 12, 22 and 24</time_frame>
        <population>Analysis used a modified as-treated approach, limited to participants with assay data at weeks 10 or 12, and 22 or 24, and with no break in study treatment for &gt;=14 days. Off-ART analysis excluded participants who started ART. On-ART analysis excluded participants who stopped ART or had virologic rebound (confirmed HIV-1 RNA&gt;1000 copies/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent CD8 HLA-DR+/CD38+ From Week 12 to Week 24</title>
          <description>The mean of week 10 and week 12 percent CD8 HLA-DR+/CD38+ is subtracted from the mean of the week 22 and week 24 percent CD8 HLA-DR+/CD38+</description>
          <population>Analysis used a modified as-treated approach, limited to participants with assay data at weeks 10 or 12, and 22 or 24, and with no break in study treatment for &gt;=14 days. Off-ART analysis excluded participants who started ART. On-ART analysis excluded participants who stopped ART or had virologic rebound (confirmed HIV-1 RNA&gt;1000 copies/mL).</population>
          <units>percent of CD8 expressing HLA-DR+/CD38+</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="2.0" upper_limit="13.8"/>
                    <measurement group_id="O2" value="1.5" lower_limit="-2.5" upper_limit="7.0"/>
                    <measurement group_id="O3" value="-0.1" lower_limit="-3.6" upper_limit="2.7"/>
                    <measurement group_id="O4" value="-2.9" lower_limit="-4.7" upper_limit="-0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Percent CD8 HLA-DR+/CD38+ From Baseline to Week 24 in Arm A and Arm C</title>
        <description>The baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 22 and week 24 percent CD8 HLA-DR+/CD38+.</description>
        <time_frame>At Pre-entry, entry, Weeks 22 and 24</time_frame>
        <population>Analysis used a modified as-treated approach, limited to participants with assay data at baseline and weeks 22 or 24, and with no break in study treatment for &gt;=14 days. Off-ART analysis excluded participants who started ART. On-ART analysis excluded participants who stopped ART or had virologic rebound (confirmed HIV-1 RNA&gt;1000 copies/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Percent CD8 HLA-DR+/CD38+ From Baseline to Week 24 in Arm A and Arm C</title>
          <description>The baseline percent CD8 HLA-DR+/CD38+ (mean of pre-entry and entry percent CD8 HLA-DR+/CD38+) was subtracted from the mean of week 22 and week 24 percent CD8 HLA-DR+/CD38+.</description>
          <population>Analysis used a modified as-treated approach, limited to participants with assay data at baseline and weeks 22 or 24, and with no break in study treatment for &gt;=14 days. Off-ART analysis excluded participants who started ART. On-ART analysis excluded participants who stopped ART or had virologic rebound (confirmed HIV-1 RNA&gt;1000 copies/mL).</population>
          <units>percent of CD8 expressing HLA-DR+/CD38+</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" lower_limit="0" upper_limit="14.8"/>
                    <measurement group_id="O2" value="-2.4" lower_limit="-4.5" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total CD4 T Cell Count From Baseline to Week 12</title>
        <description>Baseline CD4 count (mean of pre-entry and entry CD4 count) is subtracted from the mean of week 10 and week 12 CD4 count</description>
        <time_frame>At pre-entry, entry, weeks 10 and 12</time_frame>
        <population>Analysis used a modified as-treated approach, limited to participants with assay data at baseline and weeks 10 or 12, and with no break in study treatment for &gt;=14 days. Off-ART analysis excluded participants who started ART. On-ART analysis excluded participants who stopped ART or had virologic rebound (confirmed HIV-1 RNA&gt;1000 copies/mL).</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total CD4 T Cell Count From Baseline to Week 12</title>
          <description>Baseline CD4 count (mean of pre-entry and entry CD4 count) is subtracted from the mean of week 10 and week 12 CD4 count</description>
          <population>Analysis used a modified as-treated approach, limited to participants with assay data at baseline and weeks 10 or 12, and with no break in study treatment for &gt;=14 days. Off-ART analysis excluded participants who started ART. On-ART analysis excluded participants who stopped ART or had virologic rebound (confirmed HIV-1 RNA&gt;1000 copies/mL).</population>
          <units>cells/mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27" lower_limit="-150" upper_limit="4"/>
                    <measurement group_id="O2" value="-11" lower_limit="-38" upper_limit="71"/>
                    <measurement group_id="O3" value="-6" lower_limit="-21" upper_limit="10"/>
                    <measurement group_id="O4" value="7" lower_limit="-17" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Events Grade 3 or Higher</title>
        <description>Events included signs and symptoms, laboratory abnormalities and/or clinical events grade 3 or higher which were described by site clinician blinded to the treatment arm as definitely or possibly related to the study treatment.</description>
        <time_frame>From start of study treatment to study completion at week 28</time_frame>
        <population>Analysis is based on all enrolled participants, off-ART and on-ART, who received study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Events Grade 3 or Higher</title>
          <description>Events included signs and symptoms, laboratory abnormalities and/or clinical events grade 3 or higher which were described by site clinician blinded to the treatment arm as definitely or possibly related to the study treatment.</description>
          <population>Analysis is based on all enrolled participants, off-ART and on-ART, who received study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV-1 RNA Copies/mL at Study Entry for Off-ART Participants</title>
        <description>Results reported are for HIV-1 RNA (copies/mL) at study entry for off-ART participants.</description>
        <time_frame>At Entry</time_frame>
        <population>Analysis is based on all off-ART participants with HIV-1 RNA data at entry.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>HIV-1 RNA Copies/mL at Study Entry for Off-ART Participants</title>
          <description>Results reported are for HIV-1 RNA (copies/mL) at study entry for off-ART participants.</description>
          <population>Analysis is based on all off-ART participants with HIV-1 RNA data at entry.</population>
          <units>log10 copies/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.48" lower_limit="4.02" upper_limit="4.74"/>
                    <measurement group_id="O2" value="4.42" lower_limit="4.03" upper_limit="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV-1 RNA Copies/mL at Weeks 12 and 24 for Off-ART Participants</title>
        <description>Results reported are for HIV-1 RNA (copies/mL) at week 12 and week 24 for off-ART participants.</description>
        <time_frame>At weeks 12 and 24</time_frame>
        <population>Analysis is based on all off-ART participants with HIV-1 RNA data at week 12 and week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>HIV-1 RNA Copies/mL at Weeks 12 and 24 for Off-ART Participants</title>
          <description>Results reported are for HIV-1 RNA (copies/mL) at week 12 and week 24 for off-ART participants.</description>
          <population>Analysis is based on all off-ART participants with HIV-1 RNA data at week 12 and week 24.</population>
          <units>log10 copies/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.68" lower_limit="4.46" upper_limit="4.79"/>
                    <measurement group_id="O2" value="4.28" lower_limit="4.08" upper_limit="4.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.69" lower_limit="4.31" upper_limit="4.90"/>
                    <measurement group_id="O2" value="4.61" lower_limit="4.45" upper_limit="4.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV-1 RNA Copies/mL at Study Entry for On-ART Participants</title>
        <description>Results reported are for HIV-1 RNA at study entry for on-ART participants.</description>
        <time_frame>At Entry</time_frame>
        <population>Analysis is based on all on-ART participants with HIV-1 RNA data at entry.</population>
        <group_list>
          <group group_id="O1">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>HIV-1 RNA Copies/mL at Study Entry for On-ART Participants</title>
          <description>Results reported are for HIV-1 RNA at study entry for on-ART participants.</description>
          <population>Analysis is based on all on-ART participants with HIV-1 RNA data at entry.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at or below lower limit of quantitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>above lower limit of quantitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV-1 RNA Copies/mL at Week 12 for On-ART Participants</title>
        <description>Results reported are for HIV-1 RNA at week 12 for on-ART participants.</description>
        <time_frame>At week 12</time_frame>
        <population>Analysis is based on all on-ART participants with HIV-1 RNA data at week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>HIV-1 RNA Copies/mL at Week 12 for On-ART Participants</title>
          <description>Results reported are for HIV-1 RNA at week 12 for on-ART participants.</description>
          <population>Analysis is based on all on-ART participants with HIV-1 RNA data at week 12.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at or below lower limit of quantitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>above lower limit of quantitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV-1 RNA Copies/mL at Week 24 for On-ART Participants</title>
        <description>Results reported are for HIV-1 RNA at week 24 for on-ART participants.</description>
        <time_frame>At week 24</time_frame>
        <population>Analysis is based on all on-ART participants with HIV-1 RNA data at week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>HIV-1 RNA Copies/mL at Week 24 for On-ART Participants</title>
          <description>Results reported are for HIV-1 RNA at week 24 for on-ART participants.</description>
          <population>Analysis is based on all on-ART participants with HIV-1 RNA data at week 24.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>at or below lower limit of quantitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>above lower limit of quantitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent CD8 CD38+ at Baseline</title>
        <description>Baseline CD8 CD38+ is computed as the mean of pre-entry and entry CD8 CD38+.</description>
        <time_frame>At pre-entry and entry</time_frame>
        <population>Analysis is based on all participants with assay data at pre-entry or entry.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent CD8 CD38+ at Baseline</title>
          <description>Baseline CD8 CD38+ is computed as the mean of pre-entry and entry CD8 CD38+.</description>
          <population>Analysis is based on all participants with assay data at pre-entry or entry.</population>
          <units>percent of CD8 expressing CD38+</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0" lower_limit="66.0" upper_limit="80.5"/>
                    <measurement group_id="O2" value="77.0" lower_limit="71.5" upper_limit="88.3"/>
                    <measurement group_id="O3" value="50.8" lower_limit="40.1" upper_limit="65.6"/>
                    <measurement group_id="O4" value="49.9" lower_limit="37.8" upper_limit="63.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent CD8 CD38+ at Week 12</title>
        <description>Results reported are the week 12 percentage of CD8 expressing CD38+.</description>
        <time_frame>At Week 12</time_frame>
        <population>Analysis is based on all participants with assay data at week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent CD8 CD38+ at Week 12</title>
          <description>Results reported are the week 12 percentage of CD8 expressing CD38+.</description>
          <population>Analysis is based on all participants with assay data at week 12.</population>
          <units>percent of CD8 expressing CD38+</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.5" lower_limit="67.0" upper_limit="83.0"/>
                    <measurement group_id="O2" value="79.5" lower_limit="69.0" upper_limit="88.5"/>
                    <measurement group_id="O3" value="50.9" lower_limit="37.2" upper_limit="63.6"/>
                    <measurement group_id="O4" value="51.9" lower_limit="38.7" upper_limit="63.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent CD8 CD38+ at Week 24</title>
        <description>Results reported are the week 24 percentage of CD8 expressing CD38+.</description>
        <time_frame>At Week 24</time_frame>
        <population>Analysis is based on all participants with assay data at week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent CD8 CD38+ at Week 24</title>
          <description>Results reported are the week 24 percentage of CD8 expressing CD38+.</description>
          <population>Analysis is based on all participants with assay data at week 24.</population>
          <units>percent of CD8 expressing CD38+</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.0" lower_limit="74.0" upper_limit="86.0"/>
                    <measurement group_id="O2" value="79.5" lower_limit="69.0" upper_limit="89.0"/>
                    <measurement group_id="O3" value="50.6" lower_limit="40.6" upper_limit="54.4"/>
                    <measurement group_id="O4" value="48.7" lower_limit="38.2" upper_limit="64.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent CD4 HLA-DR+/CD38+ at Baseline</title>
        <description>Baseline CD4 HLA-DR+/CD38+ is computed as the mean of pre-entry and entry CD4 HLA-DR+/CD38+.</description>
        <time_frame>At pre-entry and entry</time_frame>
        <population>Analysis is based on all participants with assay data at pre-entry or entry.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent CD4 HLA-DR+/CD38+ at Baseline</title>
          <description>Baseline CD4 HLA-DR+/CD38+ is computed as the mean of pre-entry and entry CD4 HLA-DR+/CD38+.</description>
          <population>Analysis is based on all participants with assay data at pre-entry or entry.</population>
          <units>percent of CD4 expressing HLA-DR+/CD38+</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="5.5" upper_limit="12.0"/>
                    <measurement group_id="O2" value="9.8" lower_limit="8.8" upper_limit="14.3"/>
                    <measurement group_id="O3" value="8.7" lower_limit="6.9" upper_limit="10.0"/>
                    <measurement group_id="O4" value="9.9" lower_limit="6.8" upper_limit="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent CD4 HLA-DR+/CD38+ at Week 12</title>
        <description>Results reported are the week 12 percentage of CD4 expressing HLA-DR+/CD38+.</description>
        <time_frame>At Week 12</time_frame>
        <population>Analysis is based on all participants with assay data at week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent CD4 HLA-DR+/CD38+ at Week 12</title>
          <description>Results reported are the week 12 percentage of CD4 expressing HLA-DR+/CD38+.</description>
          <population>Analysis is based on all participants with assay data at week 12.</population>
          <units>percent of CD4 expressing HLA-DR+/CD38+</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" lower_limit="4.0" upper_limit="13.0"/>
                    <measurement group_id="O2" value="10.5" lower_limit="8.0" upper_limit="14.0"/>
                    <measurement group_id="O3" value="7.7" lower_limit="4.2" upper_limit="9.2"/>
                    <measurement group_id="O4" value="9.0" lower_limit="7.0" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent CD4 HLA-DR+/CD38+ at Week 24</title>
        <description>Results reported are the week 24 percentage of CD4 expressing HLA-DR+/CD38+.</description>
        <time_frame>At Week 24</time_frame>
        <population>Analysis is based on all participants with assay data at week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent CD4 HLA-DR+/CD38+ at Week 24</title>
          <description>Results reported are the week 24 percentage of CD4 expressing HLA-DR+/CD38+.</description>
          <population>Analysis is based on all participants with assay data at week 24.</population>
          <units>percent of CD4 expressing HLA-DR+/CD38+</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" lower_limit="6.0" upper_limit="14.0"/>
                    <measurement group_id="O2" value="12.5" lower_limit="8.0" upper_limit="18.0"/>
                    <measurement group_id="O3" value="7.3" lower_limit="6.0" upper_limit="8.5"/>
                    <measurement group_id="O4" value="9.2" lower_limit="7.8" upper_limit="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IL-6, Soluble TNF-rI (sTNF-rI) and D-dimer at Baseline</title>
        <description>Baseline IL-6, sTNF-rI and D-dimer were computed as the mean of pre-entry and entry IL-6, sTNF-rI and D-dimer, respectively.</description>
        <time_frame>At pre-entry and entry</time_frame>
        <population>Analysis is based on all participants with assay data at pre-entry or entry.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>IL-6, Soluble TNF-rI (sTNF-rI) and D-dimer at Baseline</title>
          <description>Baseline IL-6, sTNF-rI and D-dimer were computed as the mean of pre-entry and entry IL-6, sTNF-rI and D-dimer, respectively.</description>
          <population>Analysis is based on all participants with assay data at pre-entry or entry.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" lower_limit="0.77" upper_limit="2.66"/>
                    <measurement group_id="O2" value="1.62" lower_limit="0.97" upper_limit="1.97"/>
                    <measurement group_id="O3" value="1.01" lower_limit="0.72" upper_limit="1.56"/>
                    <measurement group_id="O4" value="1.51" lower_limit="1.01" upper_limit="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sTNF-rI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1228.66" lower_limit="992.52" upper_limit="1359.06"/>
                    <measurement group_id="O2" value="1377.81" lower_limit="1086.72" upper_limit="1558.35"/>
                    <measurement group_id="O3" value="1316.63" lower_limit="1127.96" upper_limit="1487.45"/>
                    <measurement group_id="O4" value="1250.85" lower_limit="995.60" upper_limit="1591.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D-dimer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="286390" lower_limit="162780" upper_limit="541950"/>
                    <measurement group_id="O2" value="328460" lower_limit="188690" upper_limit="422650"/>
                    <measurement group_id="O3" value="107890" lower_limit="88440" upper_limit="151810"/>
                    <measurement group_id="O4" value="103530" lower_limit="71420" upper_limit="193330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IL-6, Soluble TNF-rI (sTNF-rI) and D-dimer at Week 12</title>
        <description>Results reported are the week 12 IL-6, sTNF-rI and D-dimer.</description>
        <time_frame>At week 12</time_frame>
        <population>Analysis is based on all participants with assay data at week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>IL-6, Soluble TNF-rI (sTNF-rI) and D-dimer at Week 12</title>
          <description>Results reported are the week 12 IL-6, sTNF-rI and D-dimer.</description>
          <population>Analysis is based on all participants with assay data at week 12.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" lower_limit="0.96" upper_limit="2.35"/>
                    <measurement group_id="O2" value="1.28" lower_limit="0.96" upper_limit="2.79"/>
                    <measurement group_id="O3" value="1.15" lower_limit="0.79" upper_limit="2.07"/>
                    <measurement group_id="O4" value="1.30" lower_limit="1.06" upper_limit="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sTNF-rI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1209.50" lower_limit="1027.01" upper_limit="1385.70"/>
                    <measurement group_id="O2" value="1347.06" lower_limit="1242.37" upper_limit="1538.05"/>
                    <measurement group_id="O3" value="1441.35" lower_limit="1149.16" upper_limit="1711.86"/>
                    <measurement group_id="O4" value="1304.77" lower_limit="1092.70" upper_limit="1473.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D-dimer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251320" lower_limit="161660" upper_limit="621030"/>
                    <measurement group_id="O2" value="319770" lower_limit="189170" upper_limit="582040"/>
                    <measurement group_id="O3" value="126540" lower_limit="102190" upper_limit="179220"/>
                    <measurement group_id="O4" value="117890" lower_limit="73540" upper_limit="207890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IL-6, Soluble TNF-rI (sTNF-rI) and D-dimer at Week 24</title>
        <description>Results reported are the week 24 IL-6, sTNF-rI and D-dimer.</description>
        <time_frame>At week 24</time_frame>
        <population>Analysis is based on all participants with assay data at week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>IL-6, Soluble TNF-rI (sTNF-rI) and D-dimer at Week 24</title>
          <description>Results reported are the week 24 IL-6, sTNF-rI and D-dimer.</description>
          <population>Analysis is based on all participants with assay data at week 24.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" lower_limit="1.10" upper_limit="2.34"/>
                    <measurement group_id="O2" value="1.18" lower_limit="0.84" upper_limit="2.74"/>
                    <measurement group_id="O3" value="1.02" lower_limit="0.80" upper_limit="1.45"/>
                    <measurement group_id="O4" value="1.27" lower_limit="1.01" upper_limit="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>sTNF-rI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1327.21" lower_limit="1056.79" upper_limit="1602.16"/>
                    <measurement group_id="O2" value="1420.30" lower_limit="1229.57" upper_limit="1600.32"/>
                    <measurement group_id="O3" value="1230.21" lower_limit="1063.46" upper_limit="1358.30"/>
                    <measurement group_id="O4" value="1176.20" lower_limit="1060.28" upper_limit="1629.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D-dimer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264240" lower_limit="210110" upper_limit="380880"/>
                    <measurement group_id="O2" value="294780" lower_limit="215400" upper_limit="615550"/>
                    <measurement group_id="O3" value="100860" lower_limit="78400" upper_limit="128350"/>
                    <measurement group_id="O4" value="124920" lower_limit="83130" upper_limit="182450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Soluble CD14 (sCD14) at Baseline</title>
        <description>Baseline sCD14 was computed as the mean of pre-entry and entry sCD14.</description>
        <time_frame>At pre-entry and entry</time_frame>
        <population>Analysis is based on all participants with assay data at pre-entry or entry.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Soluble CD14 (sCD14) at Baseline</title>
          <description>Baseline sCD14 was computed as the mean of pre-entry and entry sCD14.</description>
          <population>Analysis is based on all participants with assay data at pre-entry or entry.</population>
          <units>million pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" lower_limit="1.23" upper_limit="1.79"/>
                    <measurement group_id="O2" value="1.97" lower_limit="1.77" upper_limit="2.27"/>
                    <measurement group_id="O3" value="1.80" lower_limit="1.65" upper_limit="2.18"/>
                    <measurement group_id="O4" value="1.58" lower_limit="1.39" upper_limit="1.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Soluble CD14 (sCD14) at Week 12</title>
        <description>Results reported are the week 12 sCD14.</description>
        <time_frame>At week 12</time_frame>
        <population>Analysis is based on all participants with assay data at week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Soluble CD14 (sCD14) at Week 12</title>
          <description>Results reported are the week 12 sCD14.</description>
          <population>Analysis is based on all participants with assay data at week 12.</population>
          <units>million pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" lower_limit="1.39" upper_limit="2.05"/>
                    <measurement group_id="O2" value="1.88" lower_limit="1.64" upper_limit="2.30"/>
                    <measurement group_id="O3" value="2.04" lower_limit="1.60" upper_limit="2.21"/>
                    <measurement group_id="O4" value="1.63" lower_limit="1.35" upper_limit="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Soluble CD14 (sCD14) at Week 24</title>
        <description>Results reported are the week 24 sCD14.</description>
        <time_frame>At week 24</time_frame>
        <population>Analysis is based on all participants with assay data at week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Soluble CD14 (sCD14) at Week 24</title>
          <description>Results reported are the week 24 sCD14.</description>
          <population>Analysis is based on all participants with assay data at week 24.</population>
          <units>million pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" lower_limit="1.37" upper_limit="1.97"/>
                    <measurement group_id="O2" value="2.19" lower_limit="1.79" upper_limit="2.35"/>
                    <measurement group_id="O3" value="1.77" lower_limit="1.49" upper_limit="2.39"/>
                    <measurement group_id="O4" value="1.72" lower_limit="1.54" upper_limit="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Lipopolysaccharides (LPS) at Entry</title>
        <description>Results reported are for entry fasting LPS.</description>
        <time_frame>At entry</time_frame>
        <population>Analysis is based on all participants with assay data at entry.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Lipopolysaccharides (LPS) at Entry</title>
          <description>Results reported are for entry fasting LPS.</description>
          <population>Analysis is based on all participants with assay data at entry.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.68" lower_limit="3.79" upper_limit="31.38"/>
                    <measurement group_id="O2" value="1.64" lower_limit="0.70" upper_limit="28.98"/>
                    <measurement group_id="O3" value="8.00" lower_limit="6.00" upper_limit="10.00"/>
                    <measurement group_id="O4" value="7.00" lower_limit="2.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Lipopolysaccharides (LPS) at Week 12</title>
        <description>Results reported are the week 12 fasting LPS.</description>
        <time_frame>At week 12</time_frame>
        <population>Analysis is based on all participants with assay data at week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Lipopolysaccharides (LPS) at Week 12</title>
          <description>Results reported are the week 12 fasting LPS.</description>
          <population>Analysis is based on all participants with assay data at week 12.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.37" lower_limit="4.26" upper_limit="36.63"/>
                    <measurement group_id="O2" value="13.06" lower_limit="0.70" upper_limit="36.58"/>
                    <measurement group_id="O3" value="7.00" lower_limit="6.00" upper_limit="9.00"/>
                    <measurement group_id="O4" value="7.00" lower_limit="4.00" upper_limit="9.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Lipopolysaccharides (LPS) at Week 24</title>
        <description>Results reported are the week 24 fasting LPS.</description>
        <time_frame>At week 24</time_frame>
        <population>Analysis is based on all participants with assay data at week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Lipopolysaccharides (LPS) at Week 24</title>
          <description>Results reported are the week 24 fasting LPS.</description>
          <population>Analysis is based on all participants with assay data at week 24.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.54" lower_limit="7.56" upper_limit="37.80"/>
                    <measurement group_id="O2" value="2.83" lower_limit="0.70" upper_limit="30.57"/>
                    <measurement group_id="O3" value="7.00" lower_limit="6.00" upper_limit="9.00"/>
                    <measurement group_id="O4" value="8.00" lower_limit="6.00" upper_limit="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Activation Levels of Plasmacytoid Dendritic Cells (pDC) and Myeloid Dendritic Cells (mDC) at Baseline</title>
        <description>Baseline percent activation levels of pDC were computed as the mean of pre-entry and entry percent activation levels of pDC. Similarly, baseline percent activation levels of mDC were computed as the mean of pre-entry and entry percent activation levels of mDC.</description>
        <time_frame>At pre-entry and entry</time_frame>
        <population>Analysis is based on all participants with assay data at pre-entry or entry.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Activation Levels of Plasmacytoid Dendritic Cells (pDC) and Myeloid Dendritic Cells (mDC) at Baseline</title>
          <description>Baseline percent activation levels of pDC were computed as the mean of pre-entry and entry percent activation levels of pDC. Similarly, baseline percent activation levels of mDC were computed as the mean of pre-entry and entry percent activation levels of mDC.</description>
          <population>Analysis is based on all participants with assay data at pre-entry or entry.</population>
          <units>percentage of cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>%pDC expressing CD80+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="0.00" upper_limit="0.10"/>
                    <measurement group_id="O2" value="0.03" lower_limit="0.00" upper_limit="0.07"/>
                    <measurement group_id="O3" value="0.13" lower_limit="0.07" upper_limit="0.18"/>
                    <measurement group_id="O4" value="0.07" lower_limit="0.05" upper_limit="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%pDC expressing CD83+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.48" lower_limit="28.93" upper_limit="59.40"/>
                    <measurement group_id="O2" value="36.15" lower_limit="27.18" upper_limit="52.28"/>
                    <measurement group_id="O3" value="19.91" lower_limit="13.98" upper_limit="26.58"/>
                    <measurement group_id="O4" value="23.65" lower_limit="7.49" upper_limit="27.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%pDC expressing CD86+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.12" lower_limit="7.01" upper_limit="10.79"/>
                    <measurement group_id="O2" value="9.35" lower_limit="6.33" upper_limit="11.65"/>
                    <measurement group_id="O3" value="10.96" lower_limit="5.90" upper_limit="14.04"/>
                    <measurement group_id="O4" value="12.66" lower_limit="8.28" upper_limit="17.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%pDC expressing PDL-1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.52" lower_limit="2.00" upper_limit="6.16"/>
                    <measurement group_id="O2" value="6.13" lower_limit="3.01" upper_limit="12.99"/>
                    <measurement group_id="O3" value="4.48" lower_limit="2.53" upper_limit="8.36"/>
                    <measurement group_id="O4" value="6.49" lower_limit="2.48" upper_limit="12.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%mDC expressing CD80+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" lower_limit="0.45" upper_limit="1.49"/>
                    <measurement group_id="O2" value="0.83" lower_limit="0.47" upper_limit="1.01"/>
                    <measurement group_id="O3" value="1.31" lower_limit="0.73" upper_limit="1.62"/>
                    <measurement group_id="O4" value="1.17" lower_limit="0.76" upper_limit="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%mDC expressing CD83+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.60" lower_limit="9.51" upper_limit="55.88"/>
                    <measurement group_id="O2" value="39.94" lower_limit="21.98" upper_limit="59.07"/>
                    <measurement group_id="O3" value="48.17" lower_limit="35.51" upper_limit="65.88"/>
                    <measurement group_id="O4" value="26.08" lower_limit="12.46" upper_limit="53.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%mDC expressing CD86+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.29" lower_limit="94.13" upper_limit="98.55"/>
                    <measurement group_id="O2" value="97.52" lower_limit="95.69" upper_limit="98.50"/>
                    <measurement group_id="O3" value="96.11" lower_limit="94.31" upper_limit="98.30"/>
                    <measurement group_id="O4" value="95.38" lower_limit="90.57" upper_limit="96.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%mDC expressing PDL-1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.82" lower_limit="6.32" upper_limit="13.54"/>
                    <measurement group_id="O2" value="16.37" lower_limit="7.76" upper_limit="30.19"/>
                    <measurement group_id="O3" value="4.58" lower_limit="2.71" upper_limit="7.93"/>
                    <measurement group_id="O4" value="8.28" lower_limit="3.08" upper_limit="11.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Activation Levels of Plasmacytoid Dendritic Cells (pDC) and Myeloid Dendritic Cells (mDC) at Week 12</title>
        <description>Results reported are the week 12 percent activation levels of pDC and mDC.</description>
        <time_frame>At week 12</time_frame>
        <population>Analysis is based on all participants with assay data at week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Activation Levels of Plasmacytoid Dendritic Cells (pDC) and Myeloid Dendritic Cells (mDC) at Week 12</title>
          <description>Results reported are the week 12 percent activation levels of pDC and mDC.</description>
          <population>Analysis is based on all participants with assay data at week 12.</population>
          <units>percentage of cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>%pDC expressing CD80+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="0.03"/>
                    <measurement group_id="O2" value="0.05" lower_limit="0.00" upper_limit="0.15"/>
                    <measurement group_id="O3" value="0.10" lower_limit="0.00" upper_limit="0.20"/>
                    <measurement group_id="O4" value="0.14" lower_limit="0.00" upper_limit="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%pDC expressing CD83+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.90" lower_limit="22.60" upper_limit="55.60"/>
                    <measurement group_id="O2" value="40.49" lower_limit="30.35" upper_limit="47.90"/>
                    <measurement group_id="O3" value="14.70" lower_limit="8.28" upper_limit="24.77"/>
                    <measurement group_id="O4" value="18.20" lower_limit="8.08" upper_limit="32.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%pDC expressing CD86+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.66" lower_limit="6.50" upper_limit="8.52"/>
                    <measurement group_id="O2" value="8.48" lower_limit="5.26" upper_limit="12.22"/>
                    <measurement group_id="O3" value="13.93" lower_limit="6.55" upper_limit="17.84"/>
                    <measurement group_id="O4" value="13.64" lower_limit="8.63" upper_limit="18.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%pDC expressing PDL-1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.74" lower_limit="2.66" upper_limit="5.98"/>
                    <measurement group_id="O2" value="8.43" lower_limit="3.27" upper_limit="16.53"/>
                    <measurement group_id="O3" value="7.24" lower_limit="2.24" upper_limit="10.67"/>
                    <measurement group_id="O4" value="5.16" lower_limit="2.80" upper_limit="12.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%mDC expressing CD80+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" lower_limit="0.59" upper_limit="1.12"/>
                    <measurement group_id="O2" value="1.03" lower_limit="0.68" upper_limit="1.71"/>
                    <measurement group_id="O3" value="1.47" lower_limit="0.95" upper_limit="1.87"/>
                    <measurement group_id="O4" value="1.01" lower_limit="0.90" upper_limit="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%mDC expressing CD83+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.51" lower_limit="20.34" upper_limit="51.74"/>
                    <measurement group_id="O2" value="36.47" lower_limit="27.54" upper_limit="46.41"/>
                    <measurement group_id="O3" value="47.83" lower_limit="32.32" upper_limit="65.29"/>
                    <measurement group_id="O4" value="26.75" lower_limit="13.60" upper_limit="51.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%mDC expressing CD86+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.90" lower_limit="96.99" upper_limit="98.51"/>
                    <measurement group_id="O2" value="97.18" lower_limit="96.30" upper_limit="98.65"/>
                    <measurement group_id="O3" value="95.40" lower_limit="91.26" upper_limit="97.20"/>
                    <measurement group_id="O4" value="95.15" lower_limit="87.18" upper_limit="96.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%mDC expressing PDL-1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.03" lower_limit="9.12" upper_limit="17.48"/>
                    <measurement group_id="O2" value="16.32" lower_limit="9.49" upper_limit="36.81"/>
                    <measurement group_id="O3" value="7.10" lower_limit="3.18" upper_limit="10.56"/>
                    <measurement group_id="O4" value="6.09" lower_limit="2.69" upper_limit="15.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Activation Levels of Plasmacytoid Dendritic Cells (pDC) and Myeloid Dendritic Cells (mDC) at Week 24</title>
        <description>Results reported are the week 24 percent activation levels of pDC and mDC.</description>
        <time_frame>At week 24</time_frame>
        <population>Analysis is based on all participants with assay data at week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>C: Chloroquine Then Placebo for On-ART Participants</title>
            <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>D: Placebo Then Chloroquine for On-ART Participants</title>
            <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Activation Levels of Plasmacytoid Dendritic Cells (pDC) and Myeloid Dendritic Cells (mDC) at Week 24</title>
          <description>Results reported are the week 24 percent activation levels of pDC and mDC.</description>
          <population>Analysis is based on all participants with assay data at week 24.</population>
          <units>percentage of cells</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>%pDC expressing CD80+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="0.00" upper_limit="0.08"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.05"/>
                    <measurement group_id="O3" value="0.08" lower_limit="0.03" upper_limit="0.18"/>
                    <measurement group_id="O4" value="0.16" lower_limit="0.05" upper_limit="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%pDC expressing CD83+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.50" lower_limit="26.60" upper_limit="60.30"/>
                    <measurement group_id="O2" value="38.96" lower_limit="23.17" upper_limit="45.51"/>
                    <measurement group_id="O3" value="14.80" lower_limit="7.90" upper_limit="25.62"/>
                    <measurement group_id="O4" value="17.65" lower_limit="7.78" upper_limit="21.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%pDC expressing CD86+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.13" lower_limit="7.12" upper_limit="10.73"/>
                    <measurement group_id="O2" value="7.89" lower_limit="4.86" upper_limit="12.61"/>
                    <measurement group_id="O3" value="11.79" lower_limit="6.81" upper_limit="20.98"/>
                    <measurement group_id="O4" value="12.88" lower_limit="8.99" upper_limit="19.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%pDC expressing PDL-1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.34" lower_limit="1.70" upper_limit="8.08"/>
                    <measurement group_id="O2" value="7.45" lower_limit="2.83" upper_limit="15.09"/>
                    <measurement group_id="O3" value="5.63" lower_limit="2.53" upper_limit="10.83"/>
                    <measurement group_id="O4" value="6.52" lower_limit="1.05" upper_limit="12.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%mDC expressing CD80+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" lower_limit="0.36" upper_limit="1.28"/>
                    <measurement group_id="O2" value="1.12" lower_limit="0.67" upper_limit="1.34"/>
                    <measurement group_id="O3" value="0.76" lower_limit="0.65" upper_limit="1.38"/>
                    <measurement group_id="O4" value="1.39" lower_limit="0.89" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%mDC expressing CD83+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.21" lower_limit="25.74" upper_limit="49.61"/>
                    <measurement group_id="O2" value="33.19" lower_limit="24.04" upper_limit="47.68"/>
                    <measurement group_id="O3" value="36.65" lower_limit="22.35" upper_limit="52.38"/>
                    <measurement group_id="O4" value="24.14" lower_limit="12.93" upper_limit="36.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%mDC expressing CD86+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.70" lower_limit="95.80" upper_limit="99.04"/>
                    <measurement group_id="O2" value="97.05" lower_limit="95.40" upper_limit="98.31"/>
                    <measurement group_id="O3" value="96.69" lower_limit="92.46" upper_limit="97.89"/>
                    <measurement group_id="O4" value="92.41" lower_limit="89.01" upper_limit="97.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>%mDC expressing PDL-1+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.53" lower_limit="6.31" upper_limit="18.85"/>
                    <measurement group_id="O2" value="14.84" lower_limit="11.11" upper_limit="40.45"/>
                    <measurement group_id="O3" value="4.13" lower_limit="2.14" upper_limit="11.82"/>
                    <measurement group_id="O4" value="7.49" lower_limit="3.15" upper_limit="13.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs reported from start of study treatment until study completion at 28 weeks.</time_frame>
      <desc>AE reporting followed DAIDS Reporting Level, which included AEs resulting in death, congenital anomalies, fetal losses, significant disabilities, requiring hospitalization, and AEs grade 3 and higher (where grade 1=mild, 2=moderate, 3=severe, 4=life threatening/disabling, 5=death).</desc>
      <group_list>
        <group group_id="E1">
          <title>A: Chloroquine Then Placebo for Off-ART Participants</title>
          <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>B: Placebo Then Chloroquine for Off-ART Participants</title>
          <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>C: Chloroquine Then Placebo for On-ART Participants</title>
          <description>Participants received chloroquine treatment from Day 0 through the Week 12 study visit and then began chloroquine placebo treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>D: Placebo Then Chloroquine for On-ART Participants</title>
          <description>Participants received chloroquine placebo treatment from Day 0 through the Week 12 study visit and then began chloroquine treatment until the Week 24 study visit.
Chloroquine: Taken orally, once daily, at a dose of 250 mg for 12 weeks.
Placebo: Taken orally, once daily for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Oculogyric crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Retinal depigmentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Retinal pigmentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anogenital dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Genitourinary chlamydia infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Latent syphilis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Oropharyngeal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Secondary syphilis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vulvovaginitis trichomonal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood albumin abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood cholesterol</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood glucose abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anorectal human papilloma virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fibrous histiocytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Penile wart</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dependence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Paranoia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Scrotal varicose veins</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dermatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Poor personal hygiene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>ACTG Clinicaltrials.gov Coordinator</name_or_title>
      <organization>ACTG Network Coordinating Center, Social and Scientific Systems</organization>
      <phone>(301) 628-3313</phone>
      <email>ACTGCT.Gov@s-3.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

